"Etoposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Descriptor ID |
D005047
|
MeSH Number(s) |
D02.455.426.559.847.638.960.675.250 D04.615.638.960.675.250 D09.408.348.275
|
Concept/Terms |
Etoposide- Etoposide
- Demethyl Epipodophyllotoxin Ethylidine Glucoside
- Eposide
Toposar- Toposar
- Etoposide Teva
- Teva, Etoposide
|
Below are MeSH descriptors whose meaning is more general than "Etoposide".
Below are MeSH descriptors whose meaning is more specific than "Etoposide".
This graph shows the total number of publications written about "Etoposide" by people in this website by year, and whether "Etoposide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 14 | 16 |
1995 | 3 | 12 | 15 |
1996 | 3 | 12 | 15 |
1997 | 1 | 12 | 13 |
1998 | 8 | 17 | 25 |
1999 | 4 | 12 | 16 |
2000 | 2 | 8 | 10 |
2001 | 2 | 10 | 12 |
2002 | 6 | 14 | 20 |
2003 | 2 | 13 | 15 |
2004 | 2 | 11 | 13 |
2005 | 3 | 9 | 12 |
2006 | 3 | 10 | 13 |
2007 | 0 | 7 | 7 |
2008 | 0 | 11 | 11 |
2009 | 2 | 12 | 14 |
2010 | 1 | 9 | 10 |
2011 | 0 | 9 | 9 |
2012 | 0 | 6 | 6 |
2013 | 1 | 7 | 8 |
2014 | 0 | 12 | 12 |
2015 | 0 | 13 | 13 |
2016 | 1 | 7 | 8 |
2017 | 2 | 13 | 15 |
2018 | 1 | 18 | 19 |
2019 | 1 | 7 | 8 |
2020 | 0 | 6 | 6 |
2021 | 1 | 5 | 6 |
2022 | 0 | 8 | 8 |
2023 | 0 | 5 | 5 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade. Cancer Cell. 2024 Mar 11; 42(3):429-443.e4.
-
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023 12; 186:107418.
-
Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. Int J Gynecol Cancer. 2023 09 04; 33(9):1359-1369.
-
Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2023 Sep; 111(3):477-484.
-
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023 Nov-Dec; 73(6):620-652.
-
Treatment outcomes of extraskeletal Ewing sarcoma. J Surg Oncol. 2023 Jul; 128(1):105-110.
-
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med. 2022 11 03; 387(18):1649-1660.
-
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Haematologica. 2022 10 01; 107(10):2295-2303.
-
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma. Pediatr Hematol Oncol. 2023 May; 40(4):422-428.
-
Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood. 2022 09 08; 140(10):1086-1093.